Skip to main content

Table 3 Results of the generalized regression model

From: Determinants of orphan drugs prices in France: a regression analysis

Parameter

p-value for type 3 statistics

Estimate

SE

Wald 95% Confidence Limits

p-value

Intercept

 

6.7811

0.8734

5.0693

8.4929

<.0001

Prevalence

0.1073

0.1632

0.1016

−0.0360

0.3624

0.1084

Age

 Adults

0.2753

−0.1691

0.3603

−0.8754

0.5371

0.6388

 Adults, paediatric

0.0268

0.4307

−0.8173

0.8709

0.9503

 Elderly

−0.8188

0.5580

−1.9124

0.2749

0.1423

 Paediatric

0.0000

0.0000

0.0000

0.0000

.

Alternative

 No

0.0006

1.1042

0.3062

0.5041

1.7043

0.0003

 Non-pharmacological

1.7580

0.4483

0.8793

2.6368

<.0001

 One

0.1077

0.3216

−0.5227

0.7381

0.7377

 Several

0.0000

0.0000

0.0000

0.0000

.

Severity

 Not Severe

0.2602

0.2505

0.2196

−0.1799

0.6809

0.2540

 Severe

0.0000

0.0000

0.0000

0.0000

.

ATC

 A

<.0001

2.4019

0.4458

1.5282

3.2755

<.0001

 B

0.6939

0.4266

−0.1422

1.5300

0.1038

 C

0.9708

0.4344

0.1194

1.8223

0.0254

 H

2.1675

0.4308

1.3232

3.0118

<.0001

 J

−2.6030

0.7054

−3.9855

−1.2205

0.0002

 N

0.6858

0.5076

−0.3091

1.6807

0.1767

 V, R, G

−1.6830

0.3856

−2.4387

−0.9273

<.0001

 L

0.0000

0.0000

0.0000

0.0000

.

Line

 First

0.4234

0.2195

0.2738

−0.3171

0.7561

0.4227

 Subsequent

0.0000

0.0000

0.0000

0.0000

.

IAB

 I

<.0001

1.2641

0.4322

0.4169

2.1113

0.0035

 II

1.2281

0.3514

0.5394

1.9168

0.0005

 III

−0.1662

0.3763

−0.9037

0.5714

0.6588

 IV

−0.5557

0.3711

−1.2830

0.1716

0.1343

 V

0.0000

0.0000

0.0000

0.0000

.

Study

 Other

0.6266

0.6525

0.7739

−0.8643

2.1693

0.3992

 Phase II

0.1203

0.3037

−0.4748

0.7155

0.6919

 Phase III

0.0000

0.0000

0.0000

0.0000

.

Comparator

 Active

<.0001

1.5872

0.3192

0.9616

2.2128

<.0001

 No

0.4590

0.3231

−0.1743

1.0923

0.1555

 Placebo

0.0000

0.0000

0.0000

0.0000

.

Endpoint

 Hard

0.1481

−0.4280

0.2905

−0.9973

0.1413

0.1406

 Surrogate

0.0000

0.0000

0.0000

0.0000

.

Commercialisation date

 2002–2003

0.0071

−0.2061

0.5230

−1.2311

0.8188

0.6934

 2004–2005

−0.8557

0.5956

−2.0232

0.3117

0.1508

 2006–2007

0.2278

0.4836

−0.7201

1.1756

0.6377

 2008–2009

0.0529

0.4049

−0.7407

0.8466

0.8960

 2010–2011

−0.2592

0.5049

−1.2487

0.7304

0.6077

 2012–2013

0.9553

0.4206

0.1310

1.7797

0.0231

 2014–2015

0.0000

0.0000

0.0000

0.0000

.

Delay HTA/Commercialisation

0.0048

−0.0318

0.0107

−0.0527

−0.0108

0.0029

Dispersion

 

0.2105

0.0385

0.1471

0.3011

 
  1. ATC class: A Alimentary tract and metabolism; B Blood and blood forming organs; C Cardiovascular system; G Genito-urinary system and sex hormones; H Systemic hormonal preparations, excluding sex hormones and insulins; J Antiinfectives for systemic use; L Antineoplastic and immunomodulating agents; N Nervous system; R Respiratory system; V Various
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172